King Pharmaceuticals Inc. on Friday said its blood pressure drug ramipril failed to meet the main goal in a diabetes reduction assessment.

The finding suggests that a longer trial would be necessary to detect significant benefits of ramipril on the incidence of new onset diabetes and cardiovascular morbidity, the pharmaceutical company said in a statement.

Ramipril is currently marketed as Altace by King Pharmaceuticals and Wyeth to treat patients with heart disease or high blood pressure.

King Pharma's shares fell 3% to $16.05 in trading on the NYSE.